CN105481876A - Diterpene compound for treating ovarian cancer - Google Patents
Diterpene compound for treating ovarian cancer Download PDFInfo
- Publication number
- CN105481876A CN105481876A CN201511022169.8A CN201511022169A CN105481876A CN 105481876 A CN105481876 A CN 105481876A CN 201511022169 A CN201511022169 A CN 201511022169A CN 105481876 A CN105481876 A CN 105481876A
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- extract
- ovarian cancer
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a diterpene compound for treating an ovarian cancer. The diterpene compound is reported for the first time, is novel in structure and can be obtained by being extracted from dried leaves of toona sinensis, separated and purified. It is proved through in vitro experiments that the compound can inhibit the proliferative activity of ovarian cancer SKOV3 cells, distribution of a cell cycle is affected, the cancer cells are blocked in a G0/G1 phase, and the diterpene compound can be used for being developed into drugs for treating the ovarian cancer.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry leave of Chinese toon, be separated obtain a kind of and there is diterpene-kind compound for the treatment of ovarian cancer effect and preparation method thereof.
Background technology
Toona sinensis (A.Juss.) Roemor has another name called spring bud tree, Chinese toon, Ailanthus altissima, toon is called in " An Illustrated Book on Plants ", for Meliaceae (Meliaceae) Cedrela (Toona) deciduous tree, in the distinctive precious fast-growing medicinal material book of China, have the title of " Chinese mahogany ", mainly be distributed in the provinces such as the Shandong of China, Anhui, Henan, Hebei, wherein try to gain with Taihe county, Anhui, Jiaozhuo, Henan and Shan Dongxi the Chinese toon product produced again the most famous.
Chinese toon complete stool has special odor, and has very high pharmaceutical use because being rich in various bioactivators, and its leaf, bark and fruit all can be used as medicine, and applicating history is very long, begins to be loaded in Tang Materia Medica.Folium toonae sinensis bitter, warm in nature, there is heat-clearing convergence, eliminating inflammation and expelling toxin, go the effects such as eliminating dampness, cure mainly the disease such as enteritis, dysentery; In addition, Folium toonae sinensis rich vitamin C, amino acid, high-quality protein and the trace element such as phosphorus, iron, it is the famous traditional vegetables in season of China, the edible history of existing more than 2,000 year, once together offering or present imperial palace as tribute with lichee hired, is treasure rare in vegetables, the dark favor by consumers in general, be called as abroad " green health dish ", existing multiple exit is to Japan and country in Southeast Asia.Cortex toonae bitter and puckery flavor, cool in nature, there is effect of heat extraction, eliminating dampness, ease constipation hemostasis, desinsection, be clinically usually used in treatment dysentery, enteritis, urinary tract infection, have blood in stool, leukorrhea, lumbago, skelalgia of rheumatism etc.Fruit of Chinese Toona taste is arduous, warm in nature, and tool dispels the wind, effect of loose cold, pain relieving, is clinically used for the treatment of chill diseases caused by external factors, heart peratodynia, rheumatic arthritis, hernia and cold bone wind etc.
At present, the compound that in Chinese toon, isolation identification goes out mainly can be divided into flavonoid, phenols and derivative thereof, terpene (triterpene, sesquiterpene, diterpene), Phenylpropanoid Glycosides class, sulfocompound etc.Modern study shows, the chemical composition in Chinese toon has the multiple biological activitys such as antitumor, anti-oxidant, reducing blood-fat; Chinese scholars has carried out some comparatively deep researchs to the chemical composition in Chinese toon, finds the abundant species of compound contained by it, is a kind of medicinal and edible plant resource being worth studying further, DEVELOPMENT PROSPECT is good.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry leave of Chinese toon, be separated obtain a kind of there is diterpene-kind compound for the treatment of ovarian cancer effect and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry leave of Chinese toon is pulverized by (a), extract with 80 ~ 90% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 75% ethanol elution, 10 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,55:1,30:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,15:1 and 10:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, described macroporous resin is AB-8 type macroporous adsorbent resin.
Further, described alcohol heat reflux extracts the alcohol concn adopted is 85%.
A kind of pharmaceutical composition, the described compound (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in the medicine of preparation treatment ovarian cancer.
The application of described pharmaceutical composition in the medicine of preparation treatment ovarian cancer.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Preparation method: the dry leave (8kg) of Chinese toon is pulverized by (a), (25L × 3 time) are extracted with 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (355g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract AB-8 type macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, use 75% ethanol elution, 10 column volumes again, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract (136g); C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 80:1 (8 column volumes), the methylene chloride-methanol gradient elution of 55:1 (8 column volumes), 30:1 (6 column volumes), 15:1 (8 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (31g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 20:1 (8 column volumes), the methylene chloride-methanol gradient elution of 15:1 (10 column volumes) and 10:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (11g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8-10 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (228mg).
Structural identification: colourless powder; HR-ESIMS shows [M+Na]
+for m/z335.1604, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
20h
24o
3, degree of unsaturation is 9.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 600MHz): H-1 (6.65, s), H-5 (7.52, s), H-7 (3.89, d, J=12.0), H-8 (0.92, m), H-8 (1.93, m), H-9 (0.49, m), H-11 (0.68, m), H-12 (1.11, m), H-12 (1.85, m), H-13 (1.78, m), H-16 (1.89, d, J=1.0), and H-17 (5.44, s), H-17 (5.47, s), H-18 (1.01, s), and H-19 (0.86, s), H-20 (1.26, d, J=6.9); Carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 150MHz): 146.2 (CH, 1-C), 148.7 (C, 2-C), 193.6 (C, 3-C), 130.1 (C, 4-C), 147.3 (CH, 5-C), 143.9 (C, 6-C), 76.5 (CH, 7-C), 22.4 (CH
2, 8-C), 25.3 (CH, 9-C), 16.1 (C, 10-C), 19.8 (CH, 11-C), 27.1 (CH
2, 12-C), 36.3 (CH, 13-C), 91.8 (C, 14-C), 67.5 (C, 15-C), 11.1 (CH
3, 16-C), 114.8 (CH
2, 17-C), 27.6 (CH
3, 18-C), 15.1 (CH
3, 19-C), 11.2 (CH
3, 20-C); Carbon atom mark is see Fig. 1.
1hNMR composes display two bimodal methyl signals [δ H1.26 (d, J=6.9Hz, H-20) and 1.89 (d, J=1.0Hz, H-16)], two unimodal methyl signals [δ H0.86 (s, H-19), 1.01 (s, H-18)], an olefinic methene proton signal [δ H5.44 (s, H-17) and 5.47 (s, H-17)], two olefinic methine proton signal [δ H6.65 (s, H-1) and 7.52 (s, H-5)], one containing oxygen methine proton signal [δ H3.89 (d, J=12.0Hz, H-7)].
13c-NMR spectrum shows 20 carbon signals, comprise four methyl, three methylene radical (an olefinic methylene radical), (one containing oxygen methyne for six methynes, two olefinic methynes), and seven quaternary carbons (two containing oxygen quaternary carbon for a carbonyl carbon, three alkene quaternary carbons).In HMBC spectrum, H-1 (δ H6.65) and C-2 (δ C148.7), C-3 (δ C193.6), C-4 (δ C130.1), C-15 (δ C67.5), and Me-16 (δ H1.89) shows that A ring is methyl substituted α, beta-unsaturated carbonyl structure with the dependency of C-2 (δ C148.7) and C-3 (δ C193.6).In HMBC spectrum, Me-20, H-13 and H
2-12 show to be positioned at C-14 position containing oxygen quaternary carbon with the dependency containing oxygen quaternary carbon.In HMBC spectrum, the crucial dependency of H-7 and C-14 shows to there is an ehter bond between C-7 and C-14.In addition, there is an ether ring between C-14 and C-15.Two High-Field methine proton signal δ H0.49 (m, H-9) and 0.68 (m, H-11) show that this compound contains a cyclopropane base.In HMBC spectrum, methyl proton signal Me-18 and Me-19 (δ H1.01, s and 0.86, s) with the dependency of cyclopropane methyne C-9 and C-11 (δ C25.3 and 19.8), and the High-Field nuclear magnetic signal of C-10 position (δ C16.1) shows that C-10 position is connected with two methyl.In ROESY spectrum, the dependency of H-9, H-11 and Me-18 α shows that gem-dimethylcyclopropane ring is that cis merges; The dependency of Me-20 and H-11 α shows that Me-20 is α configuration.In addition, the dependency of H-9 α and H-7 shows that 7,14-oxo bridge is beta comfiguration.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and ROESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
People's serous papillary cystenoma of ovary shape cystadenocarcinoma Cell line SKOV3 is provided by the Medical experimental center of Lanzhou University.General RPMI-1640 substratum (10% foetal calf serum) is cultivated.Compound (I) is made by oneself, and HPLC normalization method purity is greater than 98%.RPMI-1640 nutrient solution, tetramethyl-azo frustrate indigo plant (MTT), dimethyl sulfoxide (DMSO) (DMSO), L-glutaminate Ke Hao biotechnology company limited.Trypsinase is purchased from Sigma Co., USA.Foetal calf serum is purchased from Hangzhou Sijiqing Biological Engineering Material Co., Ltd..Ten Second Academys base sodium sulfonate (SDS) are purchased from Xi'an Zhou Ding biotechnology limited liability company.HER2 (FITC mark) is purchased from Beijing Bo Aosen Bioisystech Co., Ltd.Acidifying HER2 (FITC mark) is purchased from Beijing Bo Aosen Bioisystech Co., Ltd.Penicillin, Streptomycin sulphate are purchased from North China Pharmaceutical Factory.
CO
2incubator (Heraeus, BB5060UV), Germany inverted phase contrast microscope (OLYMPUS, CK-40), Japan fluorescent microscope (OLYMPUSOPTICAL, A × 80, Japan), Bechtop (Purifying Equipment Co., Ltd., Suzhou), enzyme micro-plate reader (BIO-TEK company, the U.S.), low-temperature and high-speed whizzer (Beckman-Coulter company, Germany), EpicsXL flow cytometer (Beckman-Coulter company, Germany), the automatic desk-top flash arrestor (Xinhua Medical Apparatus Co., Ltd. Shandong) of R-3850 type, DHG-9245A type electric heating constant-temperature blowing drying box (Shanghai-permanent Science and Technology Ltd.), KQ-250DB type numerical control ultrasonic cleaner (Kunshan Ultrasonic Instruments Co., Ltd.), digital display constant water bath box (Shanghai Mei Xiang Instrument Ltd.), BS400S electronic molecules balance (Beijing Sai Duolisi balance company limited), 08-2 constant temperature blender with magnetic force (Shanghai balance equipment factory), TDL-5 generic centrifuge (Anting Scientific Instrument Factory, Shanghai), cryogenic refrigerator (SANYO GS company), electronics ice making case (SANYO GS company), cell cryopreservation tube (Shanghai Sheng Gong biotechnology company limited), 96 orifice plates (Ke Hao biotechnology company limited).
Two, test method
1, cell cultures
1.1 cell recovery
Put into 37 DEG C of warm water immediately after being taken out from liquid nitrogen rapidly by cryopreservation tube, rock cryopreservation tube gently, frozen thing is dissolved as early as possible, put it in Bechtop, cell suspension in it is moved into centrifuge tube, then in centrifuge tube, adds 10 times of RPMI-1640 nutrient solutions (containing 10% calf serum), centrifugal, 800rpm/min, centrifugal 5 ~ 10min, abandons supernatant, adds the RPMI-1640 nutrient solution containing 10% calf serum in cell precipitation, jog is even, puts 37 DEG C, 5%CO
2cultivate in the incubator of concentration.And indicate Cell Name and date.
1.2 passages are cultivated
When SKOV3 cell grows to 80 ~ 90% culturing bottle, discard original nutrient solution, and wash twice with the PBS prepared; With the trysinization of 0.25%, observe under being placed on inverted microscope, when seeing that cell retraction, intercellular substance increase, form become bowlder and discard Digestive system, add in a certain amount of nutrient solution and trysinization liquid, and the cell digested is blown and beaten gently with suction pipe., make it depart from culturing bottle, the centrifugal 5min of 800rpm/min, abandons supernatant; On tally, carry out cell counting under microscope, go down to posterity in 1:3 ratio, divide and be filled in culturing bottle, continue to cultivate after again supplementing appropriate nutrient solution.Note strict aseptic technique, every day observation of cell growing state.
1.3 cell cryopreservation
The cell of taking the logarithm vegetative period is with centrifugal after the tryptic digestion of 0.25%, PBS washes 2 times, the centrifugal 5min of l000rpm on low speed centrifuge, abandon supernatant liquor, add the cells frozen storing liquid containing DMSO of 1mL precooling at-20 DEG C, moving in cryopreservation tube with after suction pipe piping and druming evenly, with putting into 4 DEG C of standing 30min after sealed membrane sealing mark, proceeding to-80 DEG C after-20 DEG C of placement 2h afterwards.The cell used in one month can be stored in-80 DEG C, should move in liquid nitrogen after long-term preserver 24h by-80 DEG C.The recovery of cell and the frozen principle that should follow are melted soon for freezing slowly.
2, tetramethyl-azo blue (MTT) experiment
(1), when selecting cell (the growth 80-90%) of logarithmic phase, with 0.25% pancreatin prepared, cell is disappeared.Change well, single cell suspension is made in piping and druming lightly, and the final cell concn of adjustment is 8 × 10
4/ mL; (2) get 3 96 orifice plates, each time point 1 plate, 100 μ L/ holes, every porocyte number is 10
4carry out grouping mark; (3) divide into groups after cell attachment, if blank group (not inoculating cell), control group (only containing equivalent solvent) and experimental group (add the compound (I) of different concns, its final concentration is respectively 0.1,1,10,20,30 and 60 μm of ol/L), often group establishes 6 multiple holes; (4) 37 DEG C, 5%CO
224,48 and 72h is cultivated respectively under condition; (5), after the time arrives, after sucking supernatant liquor, every hole adds the MTT10 μ L of 5g/L; (6) add 10 μ LDMSO after cultivating 4h, multi-functional microplate test macro measures each hole optical density(OD) OD value with 490nm wavelength; (7) medicine is to the calculating of cell inhibitory rate:
Inhibiting rate (%)=(cellular control unit number-experimental group cell count)/cellular control unit number × 100%.
Experiment at least in triplicate.
3, PI staining flow cytometry (FCM) detects cell cycle and apoptosis
(1) the SKOV3 cell of taking the logarithm vegetative period, first make single cell suspension with blowing and beating gently after the trysinization prepared, adjustment cell concn is 6 × 10
5/ mL; (2) with 6 × 10
5the density of/mL is inoculated in the culturing bottle of 50mL, in 37 DEG C, 5%CO
224h is cultivated in incubator; (3) after 24h by original nutrient solution sucking-off, add isodose (7.5mL), containing the nutrient solution of the compound (I) of different concns (0,10,20 and 30 μm of ol/L), continue at 37 DEG C, 5%CO
248h is cultivated in incubator; (4) collecting cell after 48h, makes single cell suspension, after being moved into centrifuge tube with blowing and beating gently after 0.25% trysinization, centrifugal with 1000r/min, centrifugal l0min, abandoning supernatant, and fix with the ice ethanol of 4 DEG C 70%, place the refrigerator overnight of 4 DEG C; (5) secondary daily phosphate buffered saline buffer PBS clean, centrifugal, detect after abandoning supernatant and add rnase (RNAase) 150 μ L and propidium iodide (PI) dye liquor 150 μ L, lucifuge dyeing 30min at ambient temperature, uses period profile and the apoptosis situation of flow cytomery cell.Test in triplicate, and application software is analyzed.
4, PI staining flow cytometry (FCM) detects the expression rate of HER2, P-HER2 albumen
(1) the SKOV3 cell of taking the logarithm vegetative period, first make single cell suspension with blowing and beating gently after 0.25% trysinization, adjustment cell concn is l × 10
6/ mL; (2) with l × 10
6the density of/mL is inoculated in the culturing bottle of 50mL, in 37 DEG C, 5%CO
224h is cultivated in incubator; (3) the original nutrient solution of sucking-off after 24h, the nutrient solution (control group) of the nutrient solution (experimental group) of compound (I) that add isodose (12.5mL), that containing concentration be 20 μm of ol/L and not drug containing, continues at 37 DEG C, 5%CO
248h is cultivated in incubator; (4) collecting cell after 48h, first moves into the nutrient solution in culturing bottle in centrifuge tube, then uses the tryptic digestion of 0.25%, and the cell in guarantee culturing bottle and nutritive medium all move into centrifuge tube, centrifugal by 1000r/min, l0min; (5) add PBS again by the centrifugal 10min of 1000 turns/min, repeat twice; (6) treat in test tube, there are 100 μ L samples, add HER2, P-HER2 antibody receptor (dissolve with the PBS of PH=7.4,0.01M, and press 1:60 dilution) of 30 μ LFITC marks to experimental group and control group respectively, hatch 30min for 4 DEG C; (7) cell washing lotion is added, 1200 turns/min, 10min low-temperature centrifugation, 2 times repeatedly, censorship after removal supernatant; (8) expression rate of HER2, P-HER2 albumen of flow cytomery SKOV3 cell.Above-mentioned experimental procedure in triplicate.
5, data analysis
Adopt the software of SPSS17.0 to carry out statistical analysis, represent with mean ± standard deviation (X ± s).Adopt one-way analysis of variance to compare measurement data, and compare employing LSD inspection between group between two, the comparison of rate adopts chi square test, is that difference has statistical significance with P<0.05.
Three, result and conclusion
1, MTT experiment result
All occur obvious cell inhibitory effect effect after the compound (I) of different concns acts on people's adenocarcinoma ovaries SKOV3 cell 24,48 and 72h, show as OD value (absorbance A570) and reduce, inhibiting rate raises; Result between different concns group is variant, and difference has statistical significance (P<0.05), also significant difference (P<0.05) is had different action time, show that compound (I) propagation to ovarian cancer SKOV3 cell is inhibited, and its inhibiting rate is concentration and time-dependent manner.Learnt by experimental result, when concentration is 20 μm of ol/L, effect is more satisfactory.The results are shown in Table 1.
2, PI staining flow cytometry (FCM) detects the result of cell cycle
The compound (I) choosing different concns (10,20,30 μm of ol/L) acts on SKOV348h, and experimental group comparatively control group compares G
0/ G
1cell quantity in increasing trend, and S phase and G
2/ M cell quantity is minimizing trend, and when being 20 μm of ol/L with compound (I) concentration, effect is the most obvious.Compared with control group, each experimental group has statistical significance (P<0.05).G after each experimental group effect 48h
0/ G
1cell quantity be respectively 10 μm of ol/L groups (60.707 ± 2.382), 20 μm of ol/L groups (69.611 ± 2.366), 30 μm of ol/L groups (61.099 ± 1.577), the analysis showed that 30 μm of ol/L groups are compared with 10 μm of ol/L, no significant difference (P=0.809), comparing difference between all the other each concentration groups all has statistical significance (P<0.05).After each experimental group effect 48h, the cell quantity of S phase is respectively l0 μm of ol/L group (24.254 ± 3.244), 20 μm of ol/L groups (19.468 ± 0.580), 30 μm of ol/L groups (17.743 ± 1.311), wherein 30 μm of ol/L groups are compared with 20 μm of ol/L groups, no significant difference (P=0.305), all the other each concentration groups compare difference statistical significance (P<0.05).G after each experimental group effect 48h
2the cell quantity of/M phase is respectively l0 μm of ol/L group (13.276 ± 0.658), 20 μm of ol/L groups (10.624 ± 0.483), 30 μm of ol/L (21.147 ± 2.865), and comparing difference between remaining each concentration group has statistical significance (P<0.05).It can thus be appreciated that the effect that the compound of 20 μm of ol/L (I) acts on SKOV348h is best, by cell-cycle arrest in G
0/ G
1phase, make it can not enter the S phase.The results are shown in Table 2 (note: compared with control group, equal P<0.05; * G
0/ G
1during the phase, 30 μm of ol/L groups are compared with 10 μm of ol/L groups, no significant difference (P=0.809), and during S phase, 30 μm of ol/L are compared with 20 μm of ol/L, no significant difference (P=0.305); All the other G
0/ G
1, S, G
2compare between each phase group of/M, equal P<0.05.)。
3, PI staining flow cytometry (FCM) detects the expression of HER2, P-HER2
The expression of flow cytomery SKOV3 cell HER2 and P-HER2 on its surface before and after application compound (I), learn that compound (I) action effect of 20 μm of ol/L is ideal from above-mentioned experimental result, therefore this step adopts compound (I) (20 μm of ol/L) to act on SKOV3 cell 48h, the change not obvious (P=0.13) of HER2 protein expression before and after result display application compound (I), and the expression of P-HER2 albumen has obvious difference (P<0.05).The results are shown in Table 3 (note: compared with control group, * P=0.13,
#p<0.05).
Conclusion, compound (I) can suppress the proliferation activity of ovarian cancer SKOV3 cell, and the result of this experiment MTT shows, and it affects the distribution of cell cycle, and tumour cell is arrested in G
0/ G
1phase, simultaneously by being combined with the tyrosine kinases phosphorylate ATP-binding site of EGFR/HER2 acceptor, suppress its phosphorylation, and then the expression of lowering HER2, P-HER2 albumen carrys out cell death inducing.
Table 1 different concns, the compound (I) of different action time are on the impact of SKOV3 cell
The compound (I) of table 2 different concns acts on the impact of SKOV3 cell 48h cell cycle distribution
The compound (I) of table 320 μm ol/L acts on the expression of HER2, P-HER2 after SKOV3 cell 48h
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:9 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry leave of Chinese toon is pulverized by (a), extract with 80 ~ 90% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 75% ethanol elution, 10 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,55:1,30:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,15:1 and 10:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is AB-8 type macroporous adsorbent resin.
4. the preparation method of compound according to claim 2 (I), is characterized in that: it is 85% that described alcohol heat reflux extracts the alcohol concn adopted.
5. a pharmaceutical composition, is characterized in that: the compound according to claim 1 (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in the medicine of preparation treatment ovarian cancer.
7. the application of pharmaceutical composition according to claim 5 in the medicine of preparation treatment ovarian cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511022169.8A CN105481876A (en) | 2015-12-30 | 2015-12-30 | Diterpene compound for treating ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511022169.8A CN105481876A (en) | 2015-12-30 | 2015-12-30 | Diterpene compound for treating ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105481876A true CN105481876A (en) | 2016-04-13 |
Family
ID=55669190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511022169.8A Withdrawn CN105481876A (en) | 2015-12-30 | 2015-12-30 | Diterpene compound for treating ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105481876A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105481874A (en) * | 2015-12-22 | 2016-04-13 | 陈杰 | Novel diterpene compound for treating ovarian cancer |
| CN105766964A (en) * | 2016-04-23 | 2016-07-20 | 何淑琼 | Agricultural herbicide and preparation method thereof |
| CN106146291A (en) * | 2016-07-04 | 2016-11-23 | 郑飞珍 | A kind of new sesquiterpene carboxylic acid compound and preparation method thereof and medical usage |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1631409A (en) * | 2003-12-24 | 2005-06-29 | 高雄医学大学 | Extractive originated from cedrela sinensis, its preparation process and usage |
-
2015
- 2015-12-30 CN CN201511022169.8A patent/CN105481876A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1631409A (en) * | 2003-12-24 | 2005-06-29 | 高雄医学大学 | Extractive originated from cedrela sinensis, its preparation process and usage |
Non-Patent Citations (3)
| Title |
|---|
| HSUEH-LING CHANG: "《The fractionated Toona sinensis leaf extract induces apoptosis of human ovarian cancer cells and inhibits tumor growth in a murine xenograft model》", 《GYNECOLOGIC ONCOLOGY》 * |
| 沈玉萍: "《中药香椿叶的化学成分研究》", 《中国药学杂志》 * |
| 王旭波，等: "《香椿的化学成分研究进展》", 《南京中医药大学学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105481874A (en) * | 2015-12-22 | 2016-04-13 | 陈杰 | Novel diterpene compound for treating ovarian cancer |
| CN105766964A (en) * | 2016-04-23 | 2016-07-20 | 何淑琼 | Agricultural herbicide and preparation method thereof |
| CN106146291A (en) * | 2016-07-04 | 2016-11-23 | 郑飞珍 | A kind of new sesquiterpene carboxylic acid compound and preparation method thereof and medical usage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105153187A (en) | New diterpenoid as well as preparation method and medical application thereof | |
| CN105085539A (en) | Novel diterpenoid compound, preparation method thereof and medical application | |
| CN105330674A (en) | New diterpenoid compound and preparation method and medical application thereof | |
| CN105153084A (en) | Novel diterpene compound as well as preparation method and medicinal application thereof | |
| CN105330717A (en) | Novel triterpenoid and preparation method and medical application thereof | |
| CN105061197A (en) | Novel triterpene compound and preparation method and medical application of novel triterpene compound | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN105153184A (en) | New flavanone compound for treating chronic myeloid leukemia | |
| CN105153086A (en) | Novel sesquiterpenoids compound and preparation method and medical application thereof | |
| CN105294665A (en) | Novel diterpene compound for neuroprotection | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer | |
| CN105237380A (en) | Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound | |
| CN105367536A (en) | Novel iridoid and preparation method and medical application thereof | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105418539A (en) | New meroterpenoid compound as well as preparation method and pharmaceutical application thereof | |
| CN105130935A (en) | New diterpenoid compounds for treating ovarian cancer | |
| CN105524075A (en) | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound | |
| CN105294619A (en) | Novel diterpene compound and preparation method and medical application thereof | |
| CN105503896A (en) | New phloroglucin compounds, and preparation method and medical application thereof | |
| CN105348223A (en) | Novel sesquiterpenoid and preparation method and medical application thereof | |
| CN105566342A (en) | Novel diterpenoid for treating melanoma and preparation method thereof | |
| CN105669605A (en) | New diterpenoid compound and preparation method and medical application thereof | |
| CN105418545A (en) | Novel isocoumarin compound and preparation method and medical application thereof | |
| CN105481874A (en) | Novel diterpene compound for treating ovarian cancer | |
| CN106397369A (en) | Novel labdane-type diterpenoid compound, preparation method and application thereof, pharmaceutical composition and application of pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 810016 Qinghai University, 251 Ning Ning Road, Chengbei District, Qinghai, Xining Applicant after: Wu Jinfeng Address before: 213003 Jiangsu province Changzhou Yanling West Road Zhonglou District Mingjun homes 2 building room 2407 Applicant before: Wu Jinfeng |
|
| COR | Change of bibliographic data | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160413 |